Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Liabilities and Shareholders Equity (2022 - 2025)

Zentalis Pharmaceuticals has reported Liabilities and Shareholders Equity over the past 4 years, most recently at $289.0 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $289.0 million for Q4 2025, down 32.85% from a year ago — trailing twelve months through Dec 2025 was $1.4 billion (down 29.96% YoY), and the annual figure for FY2025 was $289.0 million, down 32.85%.
  • Liabilities and Shareholders Equity for Q4 2025 was $289.0 million at Zentalis Pharmaceuticals, down from $327.2 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for ZNTL hit a ceiling of $621.4 million in Q2 2023 and a floor of $289.0 million in Q4 2025.
  • Median Liabilities and Shareholders Equity over the past 4 years was $490.5 million (2023), compared with a mean of $473.3 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: increased 20.62% in 2023 and later plummeted 32.85% in 2025.
  • Zentalis Pharmaceuticals' Liabilities and Shareholders Equity stood at $539.3 million in 2022, then rose by 2.3% to $551.7 million in 2023, then fell by 22.0% to $430.3 million in 2024, then tumbled by 32.85% to $289.0 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $289.0 million (Q4 2025), $327.2 million (Q3 2025), and $351.7 million (Q2 2025) per Business Quant data.